Gabaldón Figueira, Juan CarlosRos Lucas, AlbertMartínez Peinado, NievesBlackburn, GavinLosada Galvan, IrenePosada, ElizabethBallart, CristinaEscabia, ElisaCapellades, JordiYanes, OscarPinazo, Maria-JesusGascón, JoaquimAlonso Padilla, Julio2025-01-202025-01-202024Gabaldón-Figueira JC, Ros-Lucas A, Martínez-Peinado N, Blackburn G, Losada-Galvan I, Posada E, et al. Changes in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection. Parasit Vectors. 2024 Nov 9;17(1):459. DOI: 10.1186/s13071-024-06548-31756-3305http://hdl.handle.net/10230/69170Background: Chagas disease, caused by the parasite Trypanosoma cruzi, is a zoonosis that affects more than seven million people. Current limitations on the diagnosis of the disease hinder the prognosis of patients and the evaluation of treatment efficacy, slowing the development of new therapeutic options. The infection is known to disrupt several host metabolic pathways, providing an opportunity for the identification of biomarkers. Methods: The metabolomic and lipidomic profiles of a cohort of symptomatic and asymptomatic patients with T. cruzi infection and a group of uninfected controls were analysed using liquid chromatography/mass spectrometry. Differences among all groups and changes before and after receiving anti-parasitic treatment across those with T. cruzi infection were explored. Results: Three lipids were found to differentiate between symptomatic and asymptomatic participants: 10-hydroxydecanoic acid and phosphatidylethanolamines PE(18:0/20:4) and PE(18:1/20:4). Additionally, sphinganine, 4-hydroxysphinganine, hexadecasphinganine, and other sphingolipids showed post-treatment abundance similar to that in non-infected controls. Conclusions: These molecules hold promise as potentially useful biomarkers for monitoring disease progression and treatment response in patients with chronic T. cruzi infection.application/pdfeng© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.info:eu-repo/semantics/articlehttp://dx.doi.org/10.1186/s13071-024-06548-3Trypanosoma cruziHydroxydecanoic acidChagas diseaseLipidomicsMetabolomicsPhosphatidylethanolamineSphingolipidsTreatment responseinfo:eu-repo/semantics/openAccess